TSE

Trinseo Announces Quarterly Dividend of $0.01 Per Share

Retrieved on: 
Thursday, November 16, 2023
Natural Resources, Manufacturing, Other Manufacturing, Mining, Minerals, Chemicals, Plastics, TSE, NYSE, Holding company, Trinseo

Trinseo (NYSE: TSE), a specialty material solutions provider, today announced that its Board of Directors authorized a quarterly dividend of $0.01 per share.

Key Points: 
  • Trinseo (NYSE: TSE), a specialty material solutions provider, today announced that its Board of Directors authorized a quarterly dividend of $0.01 per share.
  • The dividend will be a cash distribution payable on January 18, 2024 to shareholders of record as of the close of business on January 4, 2024.

Hitachi Systems India Pvt. Ltd. and Cyemptive Technologies Inc. Announce Agreement to Jointly Provide Cyemptive’s Award-Winning Cybersecurity Solutions to Hitachi Systems IT Customers

Retrieved on: 
Tuesday, November 14, 2023
Software, Networks, Professional Services, Internet, Contracts, Data Management, Technology, Defense, Security, Data Analytics, Homeland Security, Public Policy, Government, Consulting, Safety, Public Distribution System (India), TSE, Arms industry, Hitachi

Ltd. ("Hitachi Systems India"), a wholly owned subsidiary of Hitachi Systems (TSE: 6501), today announced their agreement with Cyemptive Technologies, Inc., an award-winning provider of preemptive cybersecurity solutions for business and government, to jointly provide Cyemptive Technology’s next-generation cybersecurity innovations, including on-demand, end-to-end secure platform solutions, to Hitachi Systems India’s Southeast Asia/Middle East and India customers.

Key Points: 
  • Ltd. ("Hitachi Systems India"), a wholly owned subsidiary of Hitachi Systems (TSE: 6501), today announced their agreement with Cyemptive Technologies, Inc., an award-winning provider of preemptive cybersecurity solutions for business and government, to jointly provide Cyemptive Technology’s next-generation cybersecurity innovations, including on-demand, end-to-end secure platform solutions, to Hitachi Systems India’s Southeast Asia/Middle East and India customers.
  • Under the terms of the agreement, Hitachi Systems India will provide Cyemptive’s cybersecurity solutions to its IT customers, starting with the India, Southeast Asia, and Middle East markets.
  • According to Hitachi Systems India, the purpose of this strategic agreement is to provide a comprehensive solution to the ever-growing financial and reputational cybersecurity risk for its customers.
  • “Together, we will effectively address the ever-growing financial and reputational cybersecurity risk for Hitachi Systems India customers.”

Renesas Announces Completion of INCJ’s Sale of Renesas Shares

Retrieved on: 
Tuesday, November 14, 2023
Networks, Professional Services, Hardware, General Automotive, Technology, Automotive, Other Manufacturing, Semiconductor, Security, Audio, Video, Finance, Other Technology, Manufacturing, Sale, INCJ, Growth, TSE, Transitron Electronic Corporation, Treasury, Security (finance), Renesas Electronics

Renesas Electronics Corporation (TSE: 6723, “Renesas”), a premier supplier of advanced semiconductor solutions, today announced that all of its shares owned by INCJ, Ltd. (“INCJ”) have been sold by INCJ (“the sale,” excluding fractional shares1).

Key Points: 
  • Renesas Electronics Corporation (TSE: 6723, “Renesas”), a premier supplier of advanced semiconductor solutions, today announced that all of its shares owned by INCJ, Ltd. (“INCJ”) have been sold by INCJ (“the sale,” excluding fractional shares1).
  • This indicates a successful exit by the Japanese state-backed fund from its investment in Renesas that supported Renesas’ transformation to profitability.
  • “10 years have passed since we invested in Renesas to support its growth in the rapidly changing semiconductor industry.
  • (Note 2) Ratio of the number of shares held to 1,769,599,472 shares, which is calculated by deducting the 188,854,551 shares of treasury stock held by Renesas as of November 13, 2023 from 1,958,454,023 shares, which is the total number of issued shares of common stock as of the same day.

Hitachi Vantara Appoints Tony Gonnella as New Chief Financial Officer

Retrieved on: 
Monday, December 18, 2023
Cortex, Hitachi, NetScout Systems, CFO, Unit, TSE, Financial management, Software as a service, Growth, NetApp, Natale Gonnella, Santa Clara University, Management, Palo Alto Networks, Science

SANTA CLARA, Calif., Dec. 18, 2023 /PRNewswire/ -- Hitachi Vantara, the data storage, infrastructure, and hybrid cloud management subsidiary of Hitachi, Ltd. (TSE: 6501), today announced that Tony Gonnella has joined the company as its new chief financial officer (CFO), effective immediately.

Key Points: 
  • SANTA CLARA, Calif., Dec. 18, 2023 /PRNewswire/ -- Hitachi Vantara, the data storage, infrastructure, and hybrid cloud management subsidiary of Hitachi, Ltd. (TSE: 6501), today announced that Tony Gonnella has joined the company as its new chief financial officer (CFO), effective immediately.
  • Gonnella reports directly to Sheila Rohra, Hitachi Vantara's chief executive officer, and will serve on the company's executive committee.
  • A seasoned finance executive, Gonnella brings more than 20 years of financial planning, financial management reporting, corporate budgeting, financial analysis, high-growth and high-profit P&L management, financial transformation, and system and process implementation experience to the role.
  • Gonnella succeeds former CFO Inigo Mazquiaran, who recently transitioned within the Hitachi Group to become the CFO of the newly formed Hitachi Digital Services organization.

EMA Recommends Arpraziquantel for Treatment of Schistosomiasis in Preschool-Aged Children

Retrieved on: 
Sunday, December 17, 2023
World Health Organization, European Medicines Agency, Consortium, Access to medicines, WHO, Tablet, ATH, EMA, Patient, European, Collaboration, Vaccine, CHMP, TSE, Committee, Partnership, Water, Schistosomiasis, Pharmaceutical industry, Astellas Pharma, Merck, Health, Access

TOKYO, Dec. 17, 2023 /PRNewswire/ -- Astellas Pharma Inc. (TSE: 4503, President and CEO: Naoki Okamura, "Astellas") contributed to the development of a pediatric formulation to treat schistosomiasis as a member of the Pediatric Praziquantel Consortium (Consortium). The Consortium announced that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) adopted a positive scientific opinion for arpraziquantel to treat one of the neglected tropical diseases, schistosomiasis, in preschool-aged children (3 months to 6 years of age) on December 15. EMA assessed arpraziquantel under the EU-Medicines for all (EU-M4all) *1 procedure for high-priority medicines intended for use in countries outside the European Union. For more details on arpraziquantel, please refer to the Consortium's press release.

Key Points: 
  • EMA assessed arpraziquantel under the EU-Medicines for all (EU-M4all) *1 procedure for high-priority medicines intended for use in countries outside the European Union.
  • For more details on arpraziquantel, please refer to the Consortium's press release .
  • Astellas provided its innovative formulation technology to co-develop arpraziquantel as a member of the Consortium.
  • Initiatives in the Consortium apply to (3), and the positive CHMP scientific opinion by EMA of arpraziquantel represents a significant milestone in alignment with Astellas' Access to Health focus.

Astellas and MBC BioLabs Announce 2023 Future Innovator Prize Awarded to TippingPoint Biosciences and Altay Therapeutics

Retrieved on: 
Wednesday, December 13, 2023
Genetics, Research, SAN, Therapy, Gene, Toxicity, IND, Biotechnology, FSHD, AVM, Patient, Mission, Idiopathic pulmonary fibrosis, Doctor of Philosophy, Altai, Drug resistance, TSE, Genome, Chromatin, Factorization of polynomials, Drug discovery, Cancer, TippingPoint, MBC, San Francisco Bay Area, Facioscapulohumeral muscular dystrophy, Pharmaceutical industry, Astellas Pharma

"We extend our congratulations to TippingPoint Biosciences and Altay Therapeutics for their remarkable achievements in therapeutics research.

Key Points: 
  • "We extend our congratulations to TippingPoint Biosciences and Altay Therapeutics for their remarkable achievements in therapeutics research.
  • "It's such an honor to be a recipient of the Astellas Future Innovator Prize, which will further support TippingPoint's research," said Laura Hsieh, CEO of TippingPoint Biosciences.
  • "Astellas' deep industry expertise coupled with MBC BioLabs' resources will play integral roles in accelerating our drug discovery development and successfully implementing TippingPoint's programs.
  • Both TippingPoint Biosciences and Altay Therapeutics will reside at MBC BioLabs with the next year sponsored by Astellas.

New Post Hoc Analysis from MAVORIC Trial Sheds Light on Burden of Cutaneous T-cell Lymphoma on Health-related Quality of Life

Retrieved on: 
Monday, December 11, 2023
Well, American Society of Hematology, Mycosis fungoides, Organ, Neuropsychological test, CTCL, Cutaneous T-cell lymphoma, Central Statistics Office (India), Disease, Skin, Eastern Cooperative Oncology Group, Modified, Patient, Itch, Bivariate, Lymph, Neoplasm, TSE, Blood, ECOG, Cancer, ANOVA, Erythroderma, Society, Female, Quality of life, Children's Oncology Group, Kyowa Kirin, B-cell lymphoma

PRINCETON, N.J., Dec. 11, 2023 /PRNewswire/ -- Kyowa Kirin, Inc., an affiliate of Kyowa Kirin Co., Ltd. (Kyowa Kirin, TSE: 4151), a global specialty pharmaceutical company based in Japan, today announced health-related quality of life (HRQL) findings from a post hoc analysis of the MAVORIC trial in patients with mycosis fungoides (MF) or Sézary syndrome (SS), two subtypes of cutaneous T-cell lymphoma (CTCL). Researchers analyzed baseline data collected prior to initiation of study treatments and found the symptoms of advanced MF/SS affected HRQL across all domains, with poorer HRQL associated with being younger in age, female, having moderate or severe itching, and impaired function as measured by the Eastern Cooperative Oncology Group performance status (ECOG PS).

Key Points: 
  • Understanding how symptoms impact an individual physically, emotionally as well as in their daily life is critical," said Susan Thornton, Chief Executive Officer, Cutaneous Lymphoma Foundation and one of the study authors.
  • Bivariate analysis (t-tests and ANOVA) was used to identify demographic and medical history variables that had a relationship with HRQL.
  • LASSO (least absolute shrinkage and selection operator) regression analysis was used to identify factors that may drive poor HRQL.
  • Researchers concluded that assessing a patient's disease concerns may help guide treatment goals and therapeutic choice.

Hitachi Vantara Launches Unified Compute Platform Integrated with GKE Enterprise to Modernize and Simplify Hybrid Cloud Management

Retrieved on: 
Tuesday, December 5, 2023
Cloud, Hitachi, Organization, Acceleration, UCP, TSE, Software, Partnership, Survival, VSP, IDC, Google Cloud, Network equipment provider, Video game

SANTA CLARA, Calif., Dec. 5, 2023 /PRNewswire/ -- To support customers in their expanding cloud journeys, Hitachi Vantara, the data storage, infrastructure, and hybrid cloud management subsidiary of Hitachi, Ltd. (TSE: 6501), today announced the launch of Hitachi Unified Compute Platform (UCP) for GKE Enterprise, a new, integrated hybrid solution, with long-time partner Google Cloud. Through Google Distributed Cloud Virtual (GDCV), Hitachi UCP for GKE Enterprise offers businesses a unified platform to manage hybrid cloud operations, leading to increased efficiency, scalability, and flexibility in their infrastructure and applications.

Key Points: 
  • Through Google Distributed Cloud Virtual (GDCV), Hitachi UCP integrates with GKE Enterprise on Google Cloud to address growing demand for hybrid cloud, offering solutions for customer increased agility and flexibility
    SANTA CLARA, Calif., Dec. 5, 2023 /PRNewswire/ -- To support customers in their expanding cloud journeys, Hitachi Vantara, the data storage, infrastructure, and hybrid cloud management subsidiary of Hitachi, Ltd. (TSE: 6501), today announced the launch of Hitachi Unified Compute Platform (UCP) for GKE Enterprise , a new, integrated hybrid solution, with long-time partner Google Cloud.
  • Through Google Distributed Cloud Virtual (GDCV), Hitachi UCP for GKE Enterprise offers businesses a unified platform to manage hybrid cloud operations, leading to increased efficiency, scalability, and flexibility in their infrastructure and applications.
  • GDCV on Hitachi UCP empowers enterprises to modernize applications, optimize infrastructure and enhance security across hybrid cloud environments by combining the flexible cloud infrastructure of Hitachi UCP with the versatility and scalability of GDCV.
  • "Our collaboration brings together Hitachi Vantara's highly available, high-performance integrated cloud infrastructure and GDCV's robust container orchestration and management capabilities," said Dan McConnell, senior vice president, product management for storage and data infrastructure, Hitachi Vantara.

Ascensia Diabetes Care takes part in MedTech Europe's 'Connecting the Dots' Film Series, with a film on Eversense® CGM

Retrieved on: 
Tuesday, December 5, 2023
Safety, Practitioner, Dots, Commercial Operating System, Physician, BBC Studios, Collection, CGM, Patient, Blood glucose monitoring, TSE, BBC, Diabetes, BGM, Medical device, MedTech Europe

Parsippany, N.J.  , Dec. 5, 2023 /PRNewswire/ -- Ascensia Diabetes Care, a global diabetes care company, announces its participation in a new film series featuring the story of patient advocate and Eversense® user Troy Ita. Presented by MedTech Europe and including a film produced for the organization by BBC StoryWorks Commercial Productions, the branded content studio of BBC Studios, the 'Connecting the Dots' series brings into focus the evolution of medical technologies, celebrating both cutting-edge innovations and enduring healthcare solutions that empower people. The series is available on www.medtechconnectingthedots.com.

Key Points: 
  • Parsippany, N.J. , Dec. 5, 2023 /PRNewswire/ -- Ascensia Diabetes Care, a global diabetes care company, announces its participation in a new film series featuring the story of patient advocate and Eversense® user Troy Ita.
  • In particular, the film highlights the transformation that Eversense, the only long-term CGM system, can deliver to people with diabetes, through the lens of Troy and his endocrinologist Dr. Rakesh Patel.
  • In the film, Troy said, "I'm constantly on the road driving for my job, so managing my diabetes has become a juggling act.
  • Ascensia Diabetes Care, the maker of the CONTOUR® Blood Glucose Monitoring (BGM) System portfolio and exclusive distributor of Eversense® Continuous Glucose Monitoring (CGM) Systems, is a PHC Holdings Corporation (TSE: 6523) company.

Hitachi Vantara Introduces Pentaho+, A Simplified Platform For Trusted, GenAI-ready Data

Retrieved on: 
Thursday, November 30, 2023
Hitachi, Machine learning, Generative, Internet of things, Organization, Synthetic media, Risk, Artificial intelligence, Platform, Gartner hype cycle, TSE, Harvard Business Review, ChatGPT, Environment, Digital transformation, AI, AWS, Information technology, Video game, Retail, Pentaho, Azure, Apache Hadoop

SANTA CLARA, Calif., Nov. 30, 2023 /PRNewswire/ -- Hitachi Vantara, the data storage, infrastructure, and hybrid cloud management subsidiary of Hitachi, Ltd. (TSE: 6501), today announced Pentaho+, an integrated platform from the Pentaho software business designed to help organizations connect, enrich, and transform operations with refined, reliable data necessary for AI and Generative AI (GenAI) accuracy. Automating the work of complex data management with powerful self-service and cloud-agnostic solutions, Pentaho+ helps improve data quality by allowing organizations to effectively oversee data from inception to deployment.

Key Points: 
  • Automating the work of complex data management with powerful self-service and cloud-agnostic solutions, Pentaho+ helps improve data quality by allowing organizations to effectively oversee data from inception to deployment.
  • Pentaho Data Catalog: Pentaho Data Catalog helps discover, identify, categorize and classify data based on meaningful business context resulting in a trusted, data driven organization.
  • Pentaho Data Storage Optimizer: Gain more cost control of IT charge backs, performance, and risk of your data for your work processes.
  • Plans to expand the Pentaho+ platform with additional capabilities for data mastering, data quality, and more can be expected in the coming months.